Meloxicam vs Placebo for Mobilization

After the screening procedures confirm that the participant is eligible to participate in the
research study:

Because no one knows which of the study options is best, the participant will be "randomized"
into one of the study groups:

- G-CSF with meloxicam

- G-CSF with placebo (pills with no medicine)

Randomization means that the participants are put into a group by chance. It is like flipping
a coin. Neither the participant nor the research doctor will choose what group the
participant will be in. The participant will have an equal chance of being placed in any
group.

- Study Drug (meloxicam or placebo): If the participant takes part in this research study,
the participant will be given a study drug-dosing diary. The study drug will come as a pill
that the participant will take by mouth daily for 5 days, starting 6 days (Day -6) before the
participant is scheduled to undergo the first apheresis procedure (Day 0) and continuing
until 2 days before apheresis (Day -2). The participant will take meloxicam or placebo for a
total of 5 days. The diary will also include special instructions for taking the study
drug(s).

-G-CSF: All participants receive G-CSF as an injection under the skin (subcutaneous) in the
clinic, daily starting 4 days (Day -4) before the first apheresis procedure (Day 0). The
participant will continue to receive G-CSF for 3 days after apheresis.

- Apheresis: The participant may receive up to 4 apheresis procedures, depending on how their
body reacts to the stem cell mobilization. The participant will receive either meloxicam or
placebo in combination with G-CSF on Days -6 to -2 as described above.

Clinical Exams: While the participant is receiving this procedure, the participant will have
regular physical exams and they will be asked specific questions about any problems that they
might be having. The participant will also have blood tests every day to look at how their
bone marrow is recovering, to give possible transfusional support, and how to see how their
liver and kidneys are functioning.

Planned Follow-up: The investigators would like to keep track of the participant's medical
condition for the rest of their life. The investigators would like keep track of the
participant's medical condition for 6 months after the study to see how they are doing.

Inclusion Criteria:

- Participants must meet the following criteria on screening examination to be eligible
to participate in the study:

- Patients with hematologic malignancies for whom autologous stem cell transplantation
is deemed clinically appropriate. Patients participating in this study are patients
who are going for their first attempt at stem cell mobilization.

- Non-Hodgkin's lymphoma, or Hodgkin's lymphoma: refractory/relapsed but chemosensitive
disease. Patients with CR or PR will be eligible for this protocol.

The designation of PR requires all of the following:

- At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of
the largest dominant nodes or nodal masses. These nodes or masses should be selected
according to all of the following: they should be clearly measurable in at least 2
perpendicular dimensions; if possible they should be from disparate regions of the
body; and they should include mediastinal and retroperitoneal areas of disease
whenever these sites are involved.

- No increase should be observed in the size of other nodes, liver, or spleen.

- Splenic and hepatic nodules must regress by ≥ 50% in their SPD or, for single nodules,
in the greatest transverse diameter.

- With the exception of splenic and hepatic nodules, involvement of other organs is
usually assessable and no measurable disease should be present.

- Bone marrow assessment is irrelevant for determination of a PR if the sample was
positive before treatment. However, if positive, the cell type should be specified
(eg, large-cell lymphoma or small neoplastic B cells). Patients who achieve a CR by
the above criteria, but who have persistent morphologic bone marrow involvement will
be considered partial responders. Multiple myeloma in first or second remission.
Patients with CR or VGPR will be eligible for this protocol. [VGPR: Serum and urine
M-protein detectable by immunofixation only but not on electrophoresis or 90% or
greater reduction in serum M-protein plus urine M-protein level <100mg per 24 h]

- Ages 18-75 years

- ECOG performance status of 0, 1, or 2.

- Ability to understand and the willingness to sign a written informed consent

- Patients on NSAIDs will be eligible only when they are off NSAIDs for a month.

Exclusion Criteria:

- Participants who exhibit any of the following conditions at screening will not be
eligible for admission into the study.

- Cardiac disease: symptomatic congestive heart failure or RVG or echocardiogram
determined left ventricular ejection fraction of < 45%, active angina pectoris, or
uncontrolled hypertensionParticipants may not be receiving any other study agents.

- Pulmonary disease: severe chronic obstructive lung disease, or symptomatic restrictive
lung disease, or corrected DLCO of < 50% of predicted.

- Renal disease: serum creatinine > 2.0 mg/dl.

- Hepatic disease: SGOT or SGPT > 3 x normal; serum bilirubin >2.0 mg/dl that is not due
to Gilbert's syndrome or hemolysis

- Uncontrolled infection.

- Pregnancy or lactation

- Patients with NSAIDs allergies, including patients who have experienced a prior GI
bleed due to NSAIDs will be excluded. Patients who have had a recent GI bleed less
than 2 weeks ago will be excluded. Patients who are on therapeutic dose anticoagulants
will be excluded from this protocol.